Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
I have a TON of blog posts and videos that Ive published on the topic, Ill share links at the bottom of the post
The landmark SELECT trial demonstrated that weekly semaglutide 2.4 mg reduces major cardiovascular events by 20% in people with obesity or overweight and established heart diseaseeven in those without diabetes.[1] This finding represents a paradigm shift in cardiovascular prevention, as it's the first time a weight-loss medication has been proven to directly reduce heart attacks, strokes, and cardiovascular deaths
These medications, including semaglutide, liraglutide, dulaglutide, and now tirzepatide, demonstrate safety even in higher-risk groups
Adequate sleep is also crucial, as glutathione production and recycling occur during rest periods
A semaglutide injection is not dangerous to your heart
AI-enabled extraction from unstructured clinical documentation enabled a high-resolution evaluation of changes in disease burden across 1,161 conditions
